Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO5490248
- Development stage
- Unknown
- Lead developer
- Chugai Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
RO5490248 (also known as RG7601) is an investigational monoclonal antibody developed by Roche (specifically Chugai Pharmaceutical in Japan) that targets CD200 (Cluster of Differentiation 200). CD200 is an immunosuppressive cell surface glycoprotein that is often overexpressed in various solid tumors and hematological malignancies. By binding to CD200, RO5490248 aims to block the interaction between CD200 and its receptor (CD200R) on immune cells, thereby potentially reversing tumor-induced immunosuppression and enhancing the anti-tumor immune response. It has been evaluated in Phase I clinical trials as a monotherapy and in combination with bevacizumab for patients with advanced or recurrent solid cancers that are refractory to standard therapy.
02
Targets
CD200
Beyond the preview
Go deeper on RO5490248.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO5490248.